Factor VIII (medication)

Factor VIII is delivered by intravenous infusion. ==History==

This transfer of a plasma byproduct into the blood stream of a hemophiliac often led to the transmission of diseases such as HIV and hepatitis before purification methods were improved. In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy. == Society and culture ==

Legal status von Willebrand Factor/Coagulation Factor VIII Complex (Human) (sold under the brand name Wilate) was approved for medical use in the United States in 2009. Economics The cost of Factor VIII and similar clotting factors has been described as "highly expensive". They are so expensive that gene therapy for haemophilia might be less expensive, especially for people with severe hemophilia. == See also ==